Wan Song1, Dong Hyeon Lee1, Hwang Gyun Jeon2, Byong Chang Jeong2, Seong Il Seo2, Hyun Moo Lee2, Han Yong Choi2, Jong Wook Kim3, SangChul Lee4, Seok-Soo Byun4, Chang Wook Jeong5, Cheol Kwak5, Jin Seon Cho6, Hanjong Ahn7, Seong Soo Jeon8. 1. Department of Urology, School of Medicine, Ewha Womans University, Seoul, Korea. 2. Department of Urology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. 3. Department of Urology, Guro Hospital, Korea University, Seoul, Korea. 4. Department of Urology, Bundang Hospital, Seoul National University, Seongnam, Korea. 5. Department of Urology, Seoul National University Hospital, Seoul, Korea. 6. Department of Urology, College of Medicine, Hallym University, Chuncheon, Korea. 7. Department of Urology, Asan Medical Center, College of Medicine, University of Ulsan, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. hjahn@amc.seoul.kr. 8. Department of Urology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. seongsoojeon@gmail.com.
Abstract
PURPOSE: Oncologic outcomes of patients with pT3aN0/Nx prostate cancer (PCa) with positive surgical margins (PSM) after radical prostatectomy (RP) are heterogeneous. We investigated the impact of Gleason score (GS) on biochemical recurrence (BCR) in these patients. METHODS: A retrospective, multicenter study was performed on 795 patients with pT3aN0/Nx PCa with PSM after RP between January 2006 and December 2014. Clinicopathologic characteristics of patients were examined and onset of BCR was identified. Kaplan-Meier survival analysis was used to illustrate BCR-free survival (BFS) and Cox proportional hazard models were applied to identify factors predicting BCR. RESULTS: During the mean follow-up period of 63.9 months, BCR was identified in 274 (34.5%) patients. The 5-year BFS was 56.6% in all patients. In multivariate analysis, pathologic GS was the only significant prognostic factor for BCR in patients with pT3aN0/Nx PCa with PSM (GS 6 vs. GS 7 (3 + 4), P = 0.047; vs. GS 7 (4 + 3), P = 0.007, and vs. GS 8-10, P < 0.001). When patients were stratified according to GS, 5-year BFS was 78.6% in GS 6, 66.2% in GS 7 (3 + 4), 51.1% in GS 7 (4 + 3) and 35.5% in GS 8-10. CONCLUSIONS: In patients with pT3aN0/Nx with PSM after RP, pathologic GS is the sole independent predictor for risk stratification of BCR. These findings might be used to determine the risk and timing of BCR and to help counsel patients regarding treatment strategy and prognosis of disease on an individual basis.
PURPOSE: Oncologic outcomes of patients with pT3aN0/Nx prostate cancer (PCa) with positive surgical margins (PSM) after radical prostatectomy (RP) are heterogeneous. We investigated the impact of Gleason score (GS) on biochemical recurrence (BCR) in these patients. METHODS: A retrospective, multicenter study was performed on 795 patients with pT3aN0/Nx PCa with PSM after RP between January 2006 and December 2014. Clinicopathologic characteristics of patients were examined and onset of BCR was identified. Kaplan-Meier survival analysis was used to illustrate BCR-free survival (BFS) and Cox proportional hazard models were applied to identify factors predicting BCR. RESULTS: During the mean follow-up period of 63.9 months, BCR was identified in 274 (34.5%) patients. The 5-year BFS was 56.6% in all patients. In multivariate analysis, pathologic GS was the only significant prognostic factor for BCR in patients with pT3aN0/Nx PCa with PSM (GS 6 vs. GS 7 (3 + 4), P = 0.047; vs. GS 7 (4 + 3), P = 0.007, and vs. GS 8-10, P < 0.001). When patients were stratified according to GS, 5-year BFS was 78.6% in GS 6, 66.2% in GS 7 (3 + 4), 51.1% in GS 7 (4 + 3) and 35.5% in GS 8-10. CONCLUSIONS: In patients with pT3aN0/Nx with PSM after RP, pathologic GS is the sole independent predictor for risk stratification of BCR. These findings might be used to determine the risk and timing of BCR and to help counsel patients regarding treatment strategy and prognosis of disease on an individual basis.
Authors: John R Srigley; Peter A Humphrey; Mahul B Amin; Sam S Chang; Lars Egevad; Jonathan I Epstein; David J Grignon; James M McKiernan; Rodolfo Montironi; Andrew A Renshaw; Victor E Reuter; Thomas M Wheeler Journal: Arch Pathol Lab Med Date: 2009-10 Impact factor: 5.534
Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Badar M Mian; Patricia Troncoso; Koji Okihara; Viju Bhadkamkar; Dennis Johnston; Adriana O Reyes; R Joseph Babaian Journal: J Urol Date: 2002-04 Impact factor: 7.450
Authors: Gerald W Hull; Farhang Rabbani; Farhat Abbas; Thomas M Wheeler; Michael W Kattan; Peter T Scardino Journal: J Urol Date: 2002-02 Impact factor: 7.450
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544